Robert Foster, Pharm.D., Ph.D., is a scientist, researcher, former professor, entrepreneur, and founder of four successful biopharma companies. He is the CEO of Hepion Pharmaceuticals, a publicly traded biopharmaceutical company focused on the development of targeted therapies for chronic liver diseases, with clinical programs moving ahead in both non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC), liver cancer. Foster began working on cyclophilin drug development in 1988. Cyclophilins are a family of diverse enzymes that participate in many pathophysiological processes.